glp-1 receptor agonists should be avoided in patients with Impact of GLP- 1 Agonist Therapy High Risk for Sarcopenia | Current Nutrition Reports GI Adverse Effects of Glucagon-Like

Additionally, the U.S

doi: 10.1016/j.tem.2016.10.001 [DOI] [PubMed] [Google Scholar] 25

9 Helping plan members access effective treatments, including weight management medication, could help offset these costs and could boost employee recruitment and retention

Given the biological latency of carcinogenesis, longer-term studies are required to determine whether these signals persist or translate into clinically meaningful reductions in cancer risk

A previous study reported that anti-depressant therapy can increase the level of BDNF and subsequently boost neurogenesis, attenuate neuronal apoptosis in the depressive brain, and ultimately improve depressive mood (Sahay and Hen, 2007)

However, it is postulated from preclinical data that incorporating GCG receptor agonism may reduce food intake and increase resting energy expenditure, potentially enhancing efficacy